These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3756058)

  • 1. Pharmacokinetics of conventional and slow-release verapamil.
    Follath F; Ha HR; Schütz E; Bühler F
    Br J Clin Pharmacol; 1986; 21 Suppl 2(Suppl 2):149S-153S. PubMed ID: 3756058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of sustained-release verapamil after a single administration and at steady state.
    Mattila J; Mäntylä R; Taskinen J; Männistö P
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):133-8. PubMed ID: 3840089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations.
    Jørgensen NP; Walstad RA
    Pharmacol Toxicol; 1988 Aug; 63(2):105-7. PubMed ID: 3186615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels and urinary excretion of verapamil, norverapamil, N-dealkylverapamil (D617), N-dealkylnorverapamil (D620) following oral administration of a slow-release preparation.
    Barbieri E; Padrini R; Piovan D; Toffoli M; Cargnelli G; Trevi G; Ferrari M
    Int J Clin Pharmacol Res; 1985; 5(2):99-107. PubMed ID: 4018947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum concentration and antihypertensive effect of slow-release verapamil.
    Schütz E; Ha HR; Bühler FR; Follath F
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S346-9. PubMed ID: 6184566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once a day verapamil in essential hypertension.
    Müller FB; Ha HR; Hotz H; Schmidlin O; Follath F; Bühler FR
    Br J Clin Pharmacol; 1986; 21 Suppl 2(Suppl 2):143S-147S. PubMed ID: 3530298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new sustained-release formulation of verapamil in the treatment of hypertension.
    Midtbo KA; Hals O; Lauve O
    J Clin Hypertens; 1986 Sep; 2(3 Suppl):125S-132S. PubMed ID: 3540222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of age on the pharmacodynamics and pharmacokinetics of two formulations of verapamil.
    Hosie J; Hosie G; Meredith PA
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S60-2. PubMed ID: 2475690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug input rate from the GI-tract. Michaelis-Menten kinetics and the bioavailability of slow release verapamil and nifedipine.
    Woodcock BG; Menke G; Fischer A; Köhne H; Rietbrock N
    Drug Des Deliv; 1988 May; 2(4):299-310. PubMed ID: 3255321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of sustained-release verapamil: automatic ambulatory blood pressure monitoring.
    Zachariah PK; Sheps SG; Schriger A
    J Clin Hypertens; 1986 Sep; 2(3 Suppl):133S-142S. PubMed ID: 3540223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular effects of verapamil in patients with essential hypertension.
    Schmieder RE; Messerli FH; Garavaglia GE; Nunez BD
    Circulation; 1987 May; 75(5):1030-6. PubMed ID: 3568303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of food on the bioavailability of a sustained-release verapamil preparation.
    Conway EL; Phillips PA; Drummer OH; Louis WJ
    J Pharm Sci; 1990 Mar; 79(3):228-31. PubMed ID: 2338632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Plasma levels and noninvasive hemodynamic profile of slow release verapamil (240 mg). A multicenter study].
    Vulpis V; Seccia TM; Ricci S; Pirrelli A
    Riv Eur Sci Med Farmacol; 1993; 15(5-6):227-35. PubMed ID: 7761676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy, safety, and kinetics of immediate- and slow-release verapamil in hispanic patients with essential hypertension.
    Fuenmayor NT; Faggin BM; Cubeddu LX
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S53-6. PubMed ID: 2475688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics and pharmacodynamics of verapamil in healthy volunteers after single oral and sublingual administration].
    Woodcock BG; Wörner P; Rietbrock N; Schwabe L; Frömming KH
    Arzneimittelforschung; 1982; 32(12):1567-71. PubMed ID: 6891597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of bioavailability of experimental single-unit sustained release tablets of verapamil hydrochloride using the stable isotope technique.
    Marvola M; Kannikoski A; Taskinen J; Ottoila P
    J Pharm Pharmacol; 1985 Nov; 37(11):766-70. PubMed ID: 2867156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of verapamil.
    Hamann SR; Blouin RA; McAllister RG
    Clin Pharmacokinet; 1984; 9(1):26-41. PubMed ID: 6362951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of oral verapamil therapy on antipyrine clearance.
    Rumiantsev DO; Piotrovskii VK; Riabokon OS; Slastnikova ID; Kokurina EV; Metelitsa VI
    Br J Clin Pharmacol; 1986 Nov; 22(5):606-9. PubMed ID: 3790408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained-release verapamil: multiple-dose pharmacokinetic comparison of 120-mg and 240-mg tablets and the effect of halving a 240-mg tablet.
    McEwen J; Durnin C; McMurdo ME; Moreland TA
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S57-9. PubMed ID: 2475689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients.
    Fuenmayor NT; Faggin BM; Cubeddu LX
    Drugs; 1992; 44 Suppl 1():1-11. PubMed ID: 1283570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.